A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

被引：0
|
作者：
Furie, Richard [1 ]
Morand, Eric [2 ]
Bruce, Ian [3 ]
Manzi, Susan [4 ]
Kalunian, Kenneth [5 ]
Vital, Edward [6 ]
Lawrence-Ford, Theresa [7 ]
Gupta, Ramesh [8 ]
Hiepe, Falk [9 ]
Santiago, Mittermayer [10 ]
Brohawn, Philip [11 ]
Berglind, Anna [12 ]
Tummala, Raj [11 ]
机构：
[1] Zucker Sch Med Hofstra Northwell, New York, NY USA
[2] Monash Univ, Melbourne, Vic, Australia
[3] Univ Manchester, Manchester, Lancs, England
[4] Allegheny Hlth Network, Pittsburgh, PA USA
[5] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA
[6] Univ Leeds, Leeds, W Yorkshire, England
[7] North Georgia Rheumatol, Lawrenceville, GA USA
[8] Baptist Mem Hosp, Memphis, TN 38146 USA
[9] Charite, Berlin, Germany
[10] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil
[11] AstraZeneca, Gaithersburg, MD USA
[12] AstraZeneca, Gothenburg, Sweden
来源：
ARTHRITIS & RHEUMATOLOGY | 2019年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1763
引用
收藏
页数：3
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF THE SECOND PHASE 3 RANDOMIZED CONTROLLED TRIAL
    Morand, Eric F.
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian N.
    Askanase, Anca D.
    Richez, Christophe
    Bae, Sang-Cheol
    Brohawn, Mr Philip Z.
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 22 - 23
  • [2] Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
    Morand, Eric
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian
    Askanase, Anca
    Riche'z, Christophe
    Bae, Sang-Cheol
    Brohawn, Philip
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
    Furie, Richard
    Morand, Eric F.
    Askanase, Anca D.
    Vital, Edward M.
    Merrill, Joan T.
    Kalyani, Rubana N.
    Abreu, Gabriel
    Pineda, Lilia
    Tummala, Raj
    [J]. LUPUS, 2021, 30 (08) : 1254 - 1263
  • [4] Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
    Chia, Yen Lin
    Tummala, Raj
    Mai, Tu H.
    Rouse, Tomas
    Streicher, Katie
    White, Wendy, I
    Morand, Eric F.
    Furie, Richard A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1094 - 1105
  • [5] Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
    Furie, Richard A.
    Bruce, Ian N.
    Doerner, Thomas
    Leon, Manuel Gustavo
    Leszczynski, Piotr
    Urowitz, Murray
    Haier, Birgit
    Jimenez, Teri
    Brittain, Claire
    Liu, Jiajun
    Barbey, Catherine
    Stach, Christian
    [J]. RHEUMATOLOGY, 2021, 60 (11) : 5397 - 5407
  • [6] Evaluation of the Efficacy and Safety of Anifrolumab in Moderate-to-Severe Systemic Lupus Erythematosus
    Cingireddy, Ananya Reddy
    Ramini, Navya
    Cingireddy, Anirudh Reddy
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [7] Anifrolumab for Patients with systemic Lupus erythematosus
    Erler, A.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2018, 77 (02): : 175 - 176
  • [8] Trial of Anifrolumab in Active Systemic Lupus Erythematosus
    Morand, Eric F.
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian N.
    Askanase, Anca D.
    Richez, Christophe
    Bae, Sang-Cheol
    Brohawn, Philip Z.
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (03): : 211 - 221
  • [9] Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
    Lazarus, Mark
    Newcombe, Paul
    Furie, Richard A.
    Brohawn, Philip
    White, Wendy
    Sinibaldi, Dominic
    Ferrari, Nicola
    Tummala, Raj
    Al-Mossawi, Hussein
    Vital, Edward
    Morand, Eric F.
    Muthas, Daniel
    Ramaswamy, Madhu
    [J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 714 - 715
  • [10] Anifrolumab in systemic lupus erythematosus
    Clark, Anna
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (01): : E12 - E12
12345